On Tuesday, Alkermes plc (NASDAQ:ALKS) revealed topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b, proof-of-concept study evaluating ALKS 2680 ...

If so, it might not just be regular fatigue, it could be Idiopathic Hypersomnia (IH). This neurological sleep disorder causes overwhelming daytime drowsiness, making it difficult to stay awake and ...

Secondary endpoints include change in Idiopathic Hypersomnia Severity Scale (IHSS ... the safety and efficacy of ALKS 2680 in adults with narcolepsy type 1 (NCT06358950) and narcolepsy type ...

Secondary endpoints of the Vibrance-3 study are changes in the Idiopathic Hypersomnia Severity Scale ... also being developed for the treatment of narcolepsy type 1 and type 2.

Melbourne, Australia, April 16, 2025 (GLOBE NEWSWIRE) -- iNGENū CRO, a specialist Contract Research Organization with deep expertise in the ...

Idiopathic Hypersomnia (IH) is a rare and chronic ... IH is one of the central disorders of hypersomnolence and, like narcolepsy, is a debilitating sleep disorder that can result in significant ...

DUBLIN, April 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to ...

DUBLIN, April 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to ...